

CES1 Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP9927b

Specification

CES1 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession

P23141

CES1 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 1066

Other Names

Liver carboxylesterase 1, Acyl-coenzyme A:cholesterol acyltransferase, ACAT, Brain carboxylesterase hBr1, Carboxylesterase 1, CE-1, hCE-1, Cocaine carboxylesterase, Egasyn, HMSE, Methylumbelliferyl-acetate deacetylase 1, Monocyte/macrophage serine esterase, Retinyl ester hydrolase, REH, Serine esterase 1, Triacylglycerol hydrolase, TGH, CES1, CES2, SES1

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CES1 Antibody (C-term) Blocking Peptide - Protein Information

Name CES1 (HGNC:1863)

Synonyms CES2, SES1

Function

Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs (PubMed:7980644, PubMed:9169443, PubMed:9490062, PubMed:18762277). Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester (PubMed:7980644, PubMed:9169443, PubMed:9490062, PubMed:18762277). Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine (PubMed:7980644). Catalyzes the transesterification of cocaine to form cocaethylene



(PubMed:7980644). Displays fatty acid ethyl ester synthase activity, catalyzing the ethyl esterification of oleic acid to ethyloleate (PubMed:<a href="http://www.uniprot.org/citations/7980644"

target="_blank">7980644). Converts monoacylglycerides to free fatty acids and glycerol. Hydrolyzes of 2-arachidonoylglycerol and prostaglandins (PubMed:21049984). Hydrolyzes cellular cholesteryl esters to free cholesterols and promotes reverse cholesterol transport (RCT) by facilitating both the initial and final steps in the process (PubMed:18762277, PubMed:16024911, PubMed:11015575, PubMed:16971496). First of all, allows free cholesterol efflux from macrophages to extracellular cholesterol acceptors and secondly, releases free cholesterol from lipoprotein-delivered cholesteryl esters in the liver for bile acid synthesis or direct secretion into the bile (PubMed:<a

 $\label{lem:http://www.uniprot.org/citations/18762277"} $$ href="http://www.uniprot.org/citations/18762277" target="_blank">18762277, PubMed:18599737, PubMed:16971496).$

Cellular Location

Endoplasmic reticulum lumen. Cytoplasm Lipid droplet. Note=Moves from cytoplasm to lipid droplets upon lipid loading. Associates with lipid droplets independently of triglycerides (TG) content of the droplets and hydrolyzes cholesteryl esters more efficiently from mixed droplets

Tissue Location

Expressed predominantly in liver with lower levels in heart and lung (PubMed:10562416). Expressed in macrophages (PubMed:11015575, PubMed:21049984, PubMed:18762277)

CES1 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

CES1 Antibody (C-term) Blocking Peptide - Images

CES1 Antibody (C-term) Blocking Peptide - Background

Carboxylesterase 1 is a member of a large multigene family. The enzymes encoded by these genes are responsible for the hydrolysis of ester- and amide-bond-containing drugs such as cocaine and heroin. They also hydrolize long-chain fatty acid esters and thioesters. This enzyme is known to hydrolyze aromatic and aliphatic esters and is necessary for cellular cholesterol esterification. It may also play a role in detoxification in the lung and/or protection of the central nervous system from ester or amide compounds. Carboxylesterase deficiency may be associated with non-Hodgkin lymphoma or B-cell lymphocytic leukemia.

CES1 Antibody (C-term) Blocking Peptide - References

Maruichi, T., et al. Biochem. Pharmacol. 79(2):288-295(2010)Nemoda, Z., et al. Neuropharmacology 57 (7-8), 731-733 (2009) :Na, K., et al. Proteomics 9(16):3989-3999(2009)Sanghani, S.P., et al. Protein Pept. Lett. 16(10):1207-1214(2009)